BioLife Solutions (NASDAQ:BLFS) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of BioLife Solutions (NASDAQ:BLFS) from a buy rating to a hold rating in a report issued on Saturday.

BLFS has been the topic of a number of other research reports. Lake Street Capital downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their price target for the stock from $33.00 to $31.00 in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Friday, July 17th. William Blair set a $31.00 price objective on BioLife Solutions in a report on Thursday. Craig Hallum lowered BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research report on Wednesday. Finally, Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioLife Solutions presently has an average rating of “Hold” and an average price target of $31.43.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $29.98 on Friday. BioLife Solutions has a 12 month low of $17.86 and a 12 month high of $32.23. The company has a 50-day moving average of $26.94 and a 200-day moving average of $23.55. The company has a market cap of $1.46 billion, a P/E ratio of -374.70 and a beta of 1.94.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The business had revenue of $27.50 million for the quarter, compared to analyst estimates of $25.66 million. As a group, equities research analysts anticipate that BioLife Solutions will post 0.03 EPS for the current year.

Insiders Place Their Bets

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the transaction, the insider directly owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. The trade was a 12.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold 1,200,000 shares of company stock worth $28,125,000 over the last 90 days. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Large investors have recently made changes to their positions in the business. Global Retirement Partners LLC acquired a new position in shares of BioLife Solutions during the 4th quarter valued at $30,000. Kemnay Advisory Services Inc. purchased a new stake in BioLife Solutions during the 4th quarter worth $35,000. State of Wyoming acquired a new stake in BioLife Solutions in the 1st quarter valued at $52,000. Quarry LP increased its holdings in BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its position in BioLife Solutions by 42.4% in the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 796 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.